Riemann B, Schober O
Department of Nuclear Medicine University Hospital Münster, Münster, Germany.
Minerva Endocrinol. 2009 Mar;34(1):81-7.
According to the literature, the prevalence of papillary thyroid microcarcinoma (PTMC) is increasing. To date, PMTC account for up to 30% of all differentiated thyroid cancers. Patients with PTMC have an excellent prognosis with a normal life expectancy. Because of the differential definitions of the PTMC, the therapeutic approaches of the national Scien-tific Societies have not been standardized. The therapeutic algorithms have to be adjusted with regard to thyroid surgery, radioiodine ablation and thyrotropin-suppressive therapy as well as follow-up. Recently, the Therapy Committee of the European Society of Nuclear Medicine (EANM) has recommended a risk-adapted therapy and follow-up. Risk factors which require a more aggressive therapeutic approach are multifocality, thyroid capsule infiltration, evidence of locoregional or distant metastasis and unfavourable histology. It was the aim of this review to evaluate the current therapeutic concepts in patients with PTMC from a nuclear medicine perspective.
根据文献报道，甲状腺微小乳头状癌（PTMC）的患病率正在上升。迄今为止，PTMC占所有分化型甲状腺癌的比例高达30%。PTMC患者预后良好，预期寿命正常。由于PTMC的定义存在差异，各国科学协会的治疗方法尚未标准化。治疗方案必须在甲状腺手术、放射性碘消融、促甲状腺素抑制治疗以及随访方面进行调整。最近，欧洲核医学协会（EANM）治疗委员会推荐了一种风险适应性治疗和随访方案。需要更积极治疗方法的风险因素包括多灶性、甲状腺包膜浸润、局部或远处转移的证据以及不良组织学特征。本综述的目的是从核医学角度评估PTMC患者当前的治疗理念。
